Business
While GSK did not provide a specific reason for returning Wave Life Sciences’ WVE-006, the decision comes after the asset in September 2025 came below analyst expectations in a Phase Ib/IIa AATD study.
FEATURED STORIES
With the biopharma industry performing better of late, analysts, executives and other industry watchers are “cautiously optimistic”—a term heard all over the streets of San Francisco at the J.P. Morgan Healthcare Conference earlier this month.
Attendance at the Biotech CEO Sisterhood’s annual photo of women leaders and allies in Union Square doubled this year. There’s still more work to do.
After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will capture the lion’s share of the market for on-demand use.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Researchers at a New York hospital compared Abbott’s 15-minute Abbott ID NOW test to another COVID-19 diagnostics device and found that the Abbott system missed 48% of positive cases the other device detected.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 14, 2020.
Following the announcement that Slaoui was tapped to helm Operation Warp Speed, Jim Greenwood, president and CEO of BIO, hailed that decision.
“VLPs have special immunological properties and are processed differently by the immune system so they have longer duration,” Adam Simpson, CEO of Icosavax, told BioSpace.
Although many cyber criminals have pledged not to attack healthcare providers during the COVID-19 pandemic, one expert tells CNBC that this may not extend to pharmaceutical companies.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 13, 2020.
Gilead stated that the five companies will manufacture the drug for distribution in “low-income and lower-middle-income countries, as well as several upper-middle- and high-income countries.”
With the Series A financing, the company now has now raised a total of $50.5 million to support its mission.
The company plans to open a new 90,000 square foot facility this summer. It was a facility that VIVEX’s employees helped design in order to make it as efficient as possible.
The two companies are working to develop and commercialize a particular type of therapy built on modulating RNA splicing using Skyhawk’s SkySTAR technology platform.